Puja P Khanna, MD, MPH
Clinical Professor
Email:
[email protected]
Available to mentor
Puja P Khanna, MD, MPH
Clinical Professor
Manage Your Profile
Center Memberships
-
Center MemberInstitute for Healthcare Policy and Innovation
Recent Publications
-
Khanna P. 2026 Mar 26;PresentationDiagnosis and Treatment of Gout in 2026
-
Khanna P. 2026 Mar 27;PresentationRheumatology for the Primary Care Physician
-
Baraf HSB, Khanna PP, Petronijevic M, Lortkipanidze M, Patel A, Ayesu K, Pillinger MH, Singhal A, Sobierska J, Christie J, Traber P, Azeem R, DeHaan W, Santin-Janin H, Desai B, Kivitz A. Arthritis and Rheumatology, 2026 Jan 1;Journal ArticleEfficacy and Safety of Nanoencapsulated Sirolimus Plus Pegadricase: Results From the Randomized, Placebo-Controlled Phase 3 Trials
DOI:10.1002/art.70266 PMID: 42351343 -
Khanna P. 2026 Mar 27;PresentationRheumatology for the Primary Care Physician
-
Khanna P, He L, Carlton A, Bautista Sanchez R, Khader Y. 2025 Oct 10;Proceeding / Abstract / PosterDevelopment of a patient education program to ensure medication safety during reproductive years at the Michigan Medicine Rheumatology Clinics
-
Khanna P, Keenan R. 2025 Oct 10;Proceeding / Abstract / PosterEfficacy of Pozdeutinurad (AR882) in Treatment Naïve and Suboptimally Treated Gouty Arthritis with Tophi
-
Elfadawy N, Khanna P, Azeem R, Peace B, Desai B, Qazi YA. Journal of the American Society of Nephrology, 2025 Oct 24; 36 (10S): 10.1681/asn.202519da686aJournal ArticleNanoencapsulated Sirolimus Plus Pegadricase (NASP) Reduces Gout Clinical Manifestations in Patients with Uncontrolled Gout (UG) and Stage 3 CKD
DOI:10.1681/asn.202519da686a -
Khanna P, Keenan R, Hingorani V, Shen Z, Morris S, Polvent E, Wei W, Mundell P, Yan S, Yeh LT. Annals of the Rheumatic Diseases, 2025 Jun 20; 84: 239 - 240.Journal ArticleOP0300 SAFETY AND TOLERABILITY OF POZDEUTINURAD (AR882) TREATMENT FOLLOWING LONG-TERM DOSING IN PATIENTS WITH CHRONIC GOUTY ARTHRITIS AND SUBCUTANEOUS TOPHI
DOI:10.1016/j.ard.2025.05.302